Eli Lilly, Investors

Digest more
Altria vs. Eli Lilly: What's the Better Stock for Dividend Investors?
Tobacco giant Altria (NYSE: MO) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%. Meanwhile, pharma company Eli Lilly (NYSE: LLY) offers a much lower yield of less than 1%,
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.
Is Eli Lilly and Company (LLY) the Best Gene-Editing Stock to Buy?
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best gene-editing stocks to buy.

Hims & Hers Health, Eli Lilly and weight loss

Digest more
Hims & Hers to Sell Lilly's Weight-Loss Drug on Its Telehealth Platform
(Reuters) -Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform. Shares of the company were up 8.5% in afternoon trading. Copyright 2025 Thomson Reuters.
Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.
Eli Lilly weight loss therapy added to Hims & Hers platform (update)
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic liraglutide to its platform. Read more here.
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
Eli Lilly Threatens Obesity Drug Copycat Makers After Shortage
Eli Lilly & Co. is targeting additional drug compounders and telehealth companies that make copycat versions of its weight ...
Eli Lilly (NYSE:LLY) Unveils Positive Phase 2 Results For Heart Disease Therapy Amid 5% Share Dip
Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments.
GlobalData on MSN2d
Eli Lilly’s lepodisiran cuts lipoprotein(a) by 93.9% in Phase II trial
The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly ( LLY -0.50%) has emerged ...
Explore more